Want to see TYRA full AI Analyst Report?
TYRA Stock Chart & Stats
$26.22
$0.43(1.40%)
At close: 4:00 PM EDT
$26.22
$0.43(1.40%)
Day’s Range― - ―
52-Week Range$13.35 - $40.65
Previous Close$31.22
Volume473.79K
Average Volume (3M)1.13M
Market Cap
$1.27B
Enterprise Value$1.76B
Total Cash (Recent Filing)$353.94M
Total Debt (Recent Filing)$5.58M
Price to Earnings (P/E)―
Beta1.10
Next Earnings
Nov 11, 2026EPS Estimate
-0.67Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.40
Shares Outstanding68,755,936
10 Day Avg. Volume565,114
30 Day Avg. Volume1,131,737
Financial Highlights & Ratios
PEG Ratio-0.40
Price to Book (P/B)6.05
Price to Sales (P/S)0.00
P/FCF Ratio-16.45
Enterprise Value/Market Cap1.38
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-12.75K
Enterprise Value/Ebitda-11.88
Forecast
1Y Price Target
$47.40Price Target Upside80.78% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
EPS Forecast (FY)-2.65
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Pipeline ValidationThe Phase 2 results provide meaningful clinical validation for Tyra’s lead program, combining strong response rates with durable complete responses and favorable safety. This supports progression toward registrational development and strengthens the potential value of the company’s FGFR-focused pipeline.
Funding CapacityThe large equity financing materially increases resources available for clinical development, discovery work, and working capital. Greater funding capacity should help Tyra execute its multi-indication strategy over the next several quarters, although the financing also expands its share count.
Low Leverage Balance SheetVery low leverage and substantial equity reduce near-term solvency pressure and preserve financial flexibility for research and clinical programs. The balance sheet is therefore better positioned to support development spending than a highly indebted biotech, despite ongoing operating losses.
Bears Say
Pre-revenue Business ModelTyra has no approved-product revenue to offset research and development spending, so its economic model remains dependent on successful clinical execution and future financing or partnering. Until a program reaches commercialization, cash generation cannot be supported by recurring sales.
Widening LossesLosses have expanded substantially while revenue remains absent, indicating that development spending is rising without a corresponding commercial contribution. Persistent operating deficits can erode equity over time and increase the capital required to advance multiple programs through later-stage trials.
Persistent Cash BurnThe scale and persistence of negative operating and free cash flow create an ongoing need for external funding. Continued burn may constrain development choices, make future capital raises necessary, and expose shareholders to additional dilution before any product revenue emerges.
Tyra Bioscience News
TYRA FAQ
What was Tyra Bioscience’s price range in the past 12 months?
Tyra Bioscience lowest stock price was $13.35 and its highest was $40.65 in the past 12 months.
What is Tyra Bioscience’s market cap?
Tyra Bioscience’s market cap is $1.27B.
When is Tyra Bioscience’s upcoming earnings report date?
Tyra Bioscience’s upcoming earnings report date is Nov 11, 2026 which is in 22 days.
How were Tyra Bioscience’s earnings last quarter?
Tyra Bioscience released its earnings results on Aug 06, 2026. The company reported -$0.69 earnings per share for the quarter, missing the consensus estimate of -$0.65 by -$0.04.
Is Tyra Bioscience overvalued?
According to Wall Street analysts Tyra Bioscience’s price is currently Undervalued.
Does Tyra Bioscience pay dividends?
Tyra Bioscience does not currently pay dividends.
What is Tyra Bioscience’s EPS estimate?
Tyra Bioscience’s EPS estimate is -0.67.
How many shares outstanding does Tyra Bioscience have?
Tyra Bioscience has 68,755,936 shares outstanding.
What happened to Tyra Bioscience’s price movement after its last earnings report?
Tyra Bioscience reported an EPS of -$0.69 in its last earnings report, missing expectations of -$0.65. Following the earnings report the stock price went up 4.862%.
Which hedge fund is a major shareholder of Tyra Bioscience?
Currently, no hedge funds are holding shares in TYRA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Tyra Bioscience Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$47.40 (80.78% Upside)
$47.40 (80.78% Upside)
Blogger Sentiment
Bullish
TYRA Sentiment 75%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Decreased
By 3.1M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $20.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▼ 1.0%
Last 30 Days ▲ 0.4%
Last 30 Days ▲ 0.4%
Technicals
SMA
Negative
20 days / 200 days
Momentum
24.79%
12-Months-Change
Fundamentals
Return on Equity
-46.39%
Trailing 12-Months
Asset Growth
19.24%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Tyra Bioscience
Tyra Biosciences, Inc. is a preclinical biopharmaceutical company focused on innovating treatments to tackle tumor resistance and enhance patient outcomes in oncology. Its flagship product candidate, TYRA-300, is a highly selective inhibitor of fibroblast growth factor receptor (FGFR)3, specifically engineered for the treatment of muscle-invasive bladder cancer. Beyond this, the company is advancing a pipeline of programs addressing other critical conditions, including FGFR2-related intrahepatic cholangiocarcinoma, FGFR3-associated achondroplasia, REarranged during transfection (RET) kinase aberrations, and various FGFR4-driven cancers. Tyra also leverages its proprietary SNAP platform, designed to accelerate structural drug design through an iterative molecular 'snapshot' approach. Founded in 2018, Tyra Biosciences maintains its headquarters in Carlsbad, California.
TYRA Stock 12 Month Forecast
Average Price Target
$47.40
▲(80.78% Upside)
Technical Analysis
Kura Oncology
―
Syndax Pharmaceuticals
―
Vir Biotechnology
―
Monte Rosa Therapeutics
―
ArriVent BioPharma, Inc.
―
Ownership Overview
25.78% Insiders
14.17% Mutual Funds
0.07% Other Institutional Investors
50.67% Public Companies and
Individual Investors